Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002862 · ClinicalTrials.gov registry record · Phase 1
Perillyl Alcohol in Treating Patients With Refractory Cancer
A Phase 1 study of Lymphoma and Unspecified Adult Solid Tumor, Protocol Specific, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT00002862: Completed Phase 1 study of Lymphoma and Unspecified Adult Solid Tumor, Protocol Specific, sponsored by National Cancer Institute (NCI).
NCT00002862 is a Phase 1 study of Lymphoma and Unspecified Adult Solid Tumor, Protocol Specific that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 25 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002862, a Phase 1 study of Lymphoma and Unspecified Adult Solid Tumor, Protocol Specific, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase I trial to study the effectiveness of perillyl alcohol in treating patients with refractory cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
Conditions Studied
Interventions
- DRUG perillyl alcohol
Study Locations (1)
Connecticut
- Yale Comprehensive Cancer Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 1996-10 |
| Phase | Phase 1 |
What the finished NCT00002862 record still lists
NCT00002862 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which perillyl alcohol is the first listed.
NCT00002862 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT00002862 about?
NCT00002862 is a clinical study titled "Perillyl Alcohol in Treating Patients With Refractory Cancer". Phase I trial to study the effectiveness of perillyl alcohol in treating patients with refractory cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
What is the current status of trial NCT00002862?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 1996-10.
What conditions does trial NCT00002862 study?
This clinical trial studies the following conditions: Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific.
What interventions are being tested in trial NCT00002862?
The interventions under investigation include: perillyl alcohol (DRUG).
Who is sponsoring clinical trial NCT00002862?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002862 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00002862's enrollment target sits among peer trials
25 230th of 299 higher than 66 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia